$9.28
-0.75-7.48%
al cierre: Nov 16, 4:00 PM EST
$9.23
-0.05-0.54%
After hour: 4:14 PM EST

The average analyst price target for Faeth Therapeutics is $59, 539.2% above the current price. Of 13 analysts, 13 rate it Buy. Targets range from $51 to $70. The latest change came on Nov 10, 2026, when Citigroup raised its price target on Faeth Therapeutics from $55 to $60 and kept a Buy rating.
Price Target Range — 3 Quarters
Analyst Consensus — 13 Analysts
Rating Trend — Last 9 Months